I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
U.S. regulators to approve molnupiravir on an emergency basis in early October, having halted clinical trials prematurely on the back of promising results . Merck said trial data indicated molnupiravir, which is meant to be given to patients within five days of symptoms, halves the risk of hospitalization or death in high-risk groups.
If approved, the pill—of which patients wouldfour twice a day for five days—would plug a large hole in the treatment options to fight Covid-19. There is a paucity of interventions designed to help recently symptomatic patients outside of hospital settings and typically treatments work towards either preventing infection in the first place or treating severe illness in hospitals.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Merck agrees to let other drug makers make its COVID pillLONDON (AP) — Pharmaceutical company Merck agreed to allow other drug makers worldwide to produce its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access to the potentially life-saving drug, a United Nations-backed public health organization said on Wednesday.
Les mer »
WHO says seeks more data from Merck on COVID anti-viral, from Bharat on vaccineThe World Health Organization (WHO) said on Thursday that it was seeking further data from Merck on its experimental new antiviral COVID-19 pill and hoped to issue guidance in coming weeks regarding its use for mild and moderate cases.
Les mer »
U.S. drug company Merck to share license for experimental covid-19 treatment with non-profitU.S. pharmaceutical giant Merck has agreed to share its license with a non-profit so that its experimental covid-19 drug, molnupiravir, can be manufactured widely around the world in a deal that would expand access in more than 100 countries
Les mer »
Merck Inks Deal To Share Antiviral Covid Pill With Poorer CountriesI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Les mer »
Merck signs pact to broaden generic manufacturing of COVID-19 pillMerck & Co has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment, the U.S. drugmaker and the organization announced on Wednesday.
Les mer »
Stacey Abrams group donates $1.34M to wipe out medical debtsATLANTA (AP) — The political organization led by Democratic titan Stacey Abrams is branching out into paying off medical debts. The Fair Fight Political Action Committee on Wednesday told The Associated Press it has donated $1.34 million from its political action committee to the nonprofit organization RIP Medical Debt to wipe out debt with a face value of $212 million that is owed by 108,000 people in Georgia, Arizona, Louisiana, Mississippi and Alabama.
Les mer »